This is the title of my new paper Forum for Health Economics and Policy (FHEP) and subtitle “Neurology has to assess insurance price and risk preferences.” The work is co-author with Kyi-Sin, compared to Jacob Faznore, Jeng Kim, Elizabeth Murns, Stacey Kowal, Thomas Majda and Jakub Hlavka.
First, the research uses a multiple random ladder approach to measure the ‘insurance value’ of new remedies for neurological conditions affecting dynamics and cognitive functions. Subsequently, we measured the relative risk diffraction (RRR) on the quality of life (Qol) health states. This parameter can be added to literature (eg, Muligan et al. 2024) on QOL risk preferences and can be included in the generalized risk-related cost effectiveness (GRES) structure. The essence of the study is below.
Neurological conditions adversely affect patients and society due to both decline in quality of life and high financial burden. Methods of traditional cost effectiveness, however, can evaluate neurological remedies by assuming patients, risks neutral. This study first wants to determine the amount of insurance value for fictional remedies (i) cognitive and (ii) delay physical loss of neurological conditions. In addition, this study also measures risk preferences on neurological health states to inform the parameters of generalized risk-referred effectiveness (GRS) analysis. Two National Survekshan-One-interaction, which evaluated the loss of cognitive loss and other dynamics, was administered to American residents of the age of 221 to November 2023. First, a multiple random ladder design was used for the coverage of a hypothetic for the will of the respondents, which was delayed for cognitive or cognitive or delay for mobility. Calculation of insurance value was estimated to be the preference described, which was more than the expected quality-time year (QALY), which was more than the risk neutrality-based value. Second, to measure the lack of risk, the respondents (i) to estimate the health quality (HRQOL) of life (i) The health related health states were asked using a visual analog scale, and (ii) select between two imaginary remedies, which are potentially different, which are potentially different, which are the hole and lorie (Hot, CA, and the SK Luuri. 1644-55). The apathy points of the respondents were estimated from survey reactions and used to estimate relative risk diffraction (RRA), assuming a constant relative risk diffraction utility function. N = 295 among the respondents who met inclusion criteria for cognitive survey, 64.9 % were women and the average age was 51 years (SD = 16). Delay in cognitive loss for liberal insurance coverage of a new treatment for WTP, $ 646.88 per year was $ 646.88 compared to $ 260.80 calculated under traditional (ie risk neutral) cost-effective approaches, which means a risk effective cost effectiveness of $ 248,037 per black. The respondents were at risk of risk on cognitive loss consequences, which meant 1.49 (95 % with RRA of CI: [1.29, 1.68]259 were 51.0 % of women who met the requirement of inclusion for the mobility survey in respondents and the average age was 49 years (SD = 16 years). WTP for a new treatment insurance coverage that prevents the progression of mobility loss, was $ 671.35 per year compared to $ 133.23, which prevents $ 671.35 compared to $ 133.23, which means the risk-effective cost effectiveness limit of $ 502,193 per QALY per year. Respondtures had a risk on dynamics results with an average RRA of 0.68 (95 % CI): [0.51, 0.86]Due to the insurance price, the respondents demonstrated high desire to pay for treatment that reduces the loss of cognitive and mobility, which is caused by neurological conditions. Individuals were at risk on both cognitive and dynamic neurology health states.
You can read full paper Here,
